Bespoke Extracts (BSPK) Non-Current Assets (2011 - 2025)
Bespoke Extracts (BSPK) reported Non-Current Assets of $98741.0 for Q3 2025, down 53.85% on a YoY basis from $213965.0 in Q3 2024, and down 12.08% sequentially from $112302.0 in Q2 2025.
Bespoke Extracts (BSPK) Non-Current Assets (2011 - 2025) Analysis & Trends
Bespoke Extracts (BSPK) has 15 years of Non-Current Assets data on file, last reported at $98741.0 in Q3 2025.
- For the quarter ending Q3 2025, Non-Current Assets fell 53.85% year-over-year to $98741.0; the trailing twelve-month figure through Sep 2025 stood at $529879.0 (down 45.51% YoY), and the FY2024 full-year result was $193831.0, down 28.87% from the prior year.
- Non-Current Assets declined to $98741.0 in Q3 2025, from $112302.0 in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $345982.0 in Q1 2022 to a low of $2745.0 in Q4 2021.
- A 5-year average of $201872.7 and a median of $233928.0 in 2024 frame the typical range for Non-Current Assets.
- Peak annual rise in Non-Current Assets reached 7.59% in 2021, while the deepest fall reached 92.31% in 2021.
- Tracing BSPK's Non-Current Assets over 5 years: stood at $2745.0 in 2021, then jumped by 10750.97% to $297859.0 in 2022, then dropped by 8.51% to $272521.0 in 2023, then slipped by 28.87% to $193831.0 in 2024, then plunged by 49.06% to $98741.0 in 2025.
- Business Quant data shows BSPK's Non-Current Assets at $98741.0 in Q3 2025, $112302.0 in Q2 2025, and $125005.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 36.78 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 26.33 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 8.68 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 79.20 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 3.84 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 15.70 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 25.92 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 2.47 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 9.64 Bn |
| 10 | Bespoke Extracts | 1.12 Mn | 1.11 Mn | 234,175.00 | 98,741.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 98,741.00 |
| Jun 30, 2025 | 112,302.00 |
| Mar 31, 2025 | 125,005.00 |
| Dec 31, 2024 | 193,831.00 |
| Sep 30, 2024 | 213,965.00 |
| Jun 30, 2024 | 233,928.00 |
| Mar 31, 2024 | 252,065.00 |
| Dec 31, 2023 | 272,521.00 |
| Sep 30, 2023 | 291,145.00 |
| Jun 30, 2023 | 310,435.00 |
| Mar 31, 2023 | 329,726.00 |
| Dec 31, 2022 | 297,859.00 |
| Sep 30, 2022 | 315,613.00 |
| Jun 30, 2022 | 330,808.00 |
| Mar 31, 2022 | 345,982.00 |
| Nov 30, 2021 | 2,745.00 |
| Aug 31, 2021 | 35,493.00 |
| May 31, 2021 | 36,303.00 |
| Feb 28, 2021 | 37,114.00 |
| Nov 30, 2020 | 35,675.00 |